KZIA Kazia Earnings per share for the last twelve months

KZIA (Kazia Therapeutics Ltd) - company brandmark

The 12-month EPS change reflects profit dynamics, where the current status is -6.86. Medium-term growth is expected following the results of final-stage clinical trials. Kazia Therapeutics (KZIA) generates revenue by developing drugs to treat complex brain tumors. Patent protection ensures a stable cash flow due to the lack of alternative therapies for patients.

KZIA (Kazia Therapeutics) Net earnings per share for the last 12 months history from 07/04/2022 to 11/18/2026

Kazia Therapeutics - analytical breakdowns and key metrics (KZIA)

- current quotes and average value forecast:
Basic company analysis:Kazia Therapeutics Ltd (KZIA)
Mass-produced product of Kazia

Kazia Therapeutics (KZIA) focuses on costly R&D developments of anti-tumor agents without current sales. Mathematically, this is reflected in a negative net income value distributed across the total volume of issued shares. This metric measures the business's actual ability to generate income, stripped of the influence of leverage. Analyzing the current level of the moving average earnings per share allows for an assessment of the capital burn rate. The trend of the curve here serves as an indicator of the company's survivability during the clinical trial period.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (silexion.com)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months